Share you expertise – Volunteer to Judge Pitches at Venture Devils

At the ASU Venture Devils program, on Saturday, November 16th 2024, 70-90 top student ventures will be pitching for varying amounts of seed funding from various funding tracks associated with the Venture Devils program. This large-scale event is happening in-person at ASU SkySong in Scottsdale, AZ. Volunteer VIP Judges are needed to provide thoughtful and thorough evaluations of these teams. We are looking for diverse, interdisciplinary judging panels and for consistency with this across all judging rooms. These panels will be assembled based on the sign-up response in coordination with the judges and stakeholders that are participating. We will notify you if you’ve been selected as a judge at least one week prior to the event. Continue reading

Gilead Signs Royalty-Free Voluntary Licensing Agreements with Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries  

  • License for Companies to Manufacture and Supply High-Quality, Low-Cost Versions of Lenacapavir for 120 Primarily Low- and Lower-Middle Income Countries –
  • Gilead Plans to PriceProduct at No Profit to the Company and Supply Lenacapavir Until Generic Manufacturers Fully Support Demand –
  • Agreements Also Cover Lenacapavir for HIV Treatment in Heavily Treatment-Experienced Adults with Multi-Drug Resistant HIV –

Continue reading

C-Path to Lead Comprehensive Task Force Focused on Accelerating Drug Development for Limb-Girdle Muscular Dystrophies

TUCSON, Ariz., September 30, 2024 — Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), dedicated to advancing therapeutic development for limb-girdle muscular dystrophies (LGMDs). This initiative brings together leading organizations and experts in a concerted effort to tackle the challenges associated with LGMDs drug development. LGMDs are a group of disorders that affect voluntary muscles, primarily those around the hips and shoulders.Continue reading

NIH Launches Redesigned Grants and Funding Website

NIH launched the new NIH Grants and Funding website in September. Designed with the needs of the extramural research community in mind, the new site is intended to enhance your journey through the NIH grants process with a modernized interface and powerful features to make finding critical information easier than ever. 

A key change involves a redesign of the NIH Guide for Grants and Contracts and related funding information. The new tools reduce reliance on activity codes and other NIH jargon to help you explore opportunities for funding in a more intuitive way.Continue reading

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies

Approval is supported by data from the EMERGENT clinical program demonstrating statistically significant reductions of schizophrenia symptoms

The safety and tolerability profile of COBENFY has been established across acute and long-term trials in schizophrenia
Continue reading